1-5 of 5
roflumilast
Close
Sort by
Journal Articles

Cyclic-AMP Is an Actionable Novel Regulator of PD-L1 Expression in Untransformed Lymphocytes and Diffuse Large B Cell Lymphomas

Binu Sasi, PhD, Zhijun Qiu, PhD, Shoulei Jiang, PhD, An-Ping Lin, MD, Ricardo Aguiar, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3962.
https://doi.org/10.1182/blood-2019-123155
Published: 2019
Journal Articles

Combination of Phosphodiesterase 4 (PDE4) Inhibitor Roflumilast and R-CHOP As First-Line Therapy for High-Risk Diffuse Large B Cell Lymphoma Patients

Adolfo E Diaz, MD, Matthew James Butler, MD, Anand Karnad, MD, Ricardo Aguiar, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1592.
https://doi.org/10.1182/blood-2019-124382
Published: 2019
Journal Articles

Synergism Between PDE4 and PI3Kδ Inhibitors in DLBCL: Improved Clinical Activity with the Potential for Lower Toxicity

Jeffrey Cooney, Long Wang, MD, An-Ping Lin, MD, Daifeng Jiang, PhD, Avvaru Suhasini, PhD, Ricardo C Aguiar, MD PhD
Journal: Blood
Blood (2016) 128 (22): 2938.
https://doi.org/10.1182/blood.V128.22.2938.2938
Published: 2016
Journal Articles

A Phosphodiesterase 4B-Mediated Interplay Between Tumor Cells and the Microenvironment Regulates Angiogenesis in B Cell Lymphoma

Avvaru Suhasini, Long Wang, Kenneth Holder, An-Ping Lin, Sang-Woo Kim, Harshita Bhatnagar, August Moritz, Ricardo C Aguiar, MD PhD
Journal: Blood
Blood (2015) 126 (23): 463.
https://doi.org/10.1182/blood.V126.23.463.463
Published: 2015
Journal Articles

Personalized Therapy Design for MPN Using Predictive Simulation Methodology with in Vitro, Ex Vivo, and in Vivo Validatio

Peter P. Sayeski, PhD, Shireen Vali, PhD, Ansu Kumar, Sung Park, PhD, Neeraj Kumar Singh, Anuj Tyagi, Taher Abbasi, MS, Christopher R. Cogle, MD
Journal: Blood
Blood (2014) 124 (21): 3212.
https://doi.org/10.1182/blood.V124.21.3212.3212
Published: 2014